Skip to main content
Sinocelltech Group Limited logo

Sinocelltech Group Limited — Investor Relations & Filings

Ticker · 688520 ISIN · CNE100003ZL3 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 659 across all filing types
Latest filing 2025-06-05 Capital/Financing Update
Country CN China
Listing Shanghai Stock Exchange 688520

About Sinocelltech Group Limited

https://www.sinocelltech.com/

Sinocelltech Group Limited focuses on the research, development, and commercialization of innovative biologics, including monoclonal antibodies, recombinant proteins, and vaccine candidates. The company's product pipeline addresses therapeutic areas such as oncology, autoimmune disorders, hematology, and infectious diseases. Key offerings include recombinant human coagulation factor VIII for hemophilia A and a range of biosimilars. Sinocelltech leverages an integrated technology platform encompassing early-stage discovery through to large-scale industrial production. This infrastructure supports the development of high-quality biological medicines aimed at addressing unmet medical needs through advanced protein engineering and cell line development.

Recent filings

Filing Released Lang Actions
神州细胞关于2025年度向特定对象发行A股股票预案披露的提示性公告
Capital/Financing Update Classification · 95% confidence The document is a short announcement (480 characters) regarding the company's plan to issue A shares to specific investors in 2025. It mentions the board meeting approval and that the detailed proposal is available on the stock exchange website. It explicitly states that this announcement is a preliminary disclosure and not an approval or completion of the issuance. There are no financial statements or detailed financial data included. The document is essentially an update on a capital raising plan, specifically a share issuance proposal. According to the definitions, this fits best under 'Capital/Financing Update (CAP)' as it relates to company fundraising activities and capital structure changes. The document is too short and does not contain full financial data to be classified as a full report or prospectus. Therefore, the classification is CAP with high confidence.
2025-06-05 Chinese
神州细胞关于召开2025年第一次临时股东会的通知
Proxy Solicitation & Information Statement Classification · 95% confidence The document is a detailed notice about convening the 2025 first extraordinary general meeting (临时股东会) of Beijing Sinocelltech Biotech Co., Ltd. It includes information about the meeting date, voting methods, agenda items (mostly related to a specific share issuance plan), registration procedures, and proxy authorization. There is no financial data or report content, but rather an announcement and procedural details for a shareholder meeting. This fits the category of a Proxy Solicitation & Information Statement (PSI), as it provides materials sent to shareholders to inform and request votes for the meeting. The document length is about 4531 characters, which is consistent with a detailed meeting notice and proxy materials, not a full report or results announcement. Therefore, the classification is PSI with high confidence.
2025-06-05 Chinese
中信证券股份有限公司关于北京神州细胞生物技术集团股份公司2024年度持续督导跟踪报告
Audit Report / Information Classification · 95% confidence The document is titled as a "2024年度持续督导跟踪报告" (2024 Annual Continuous Supervision Follow-up Report) issued by the sponsor (中信证券) for 北京神州细胞生物技术集团股份公司. It references regulatory frameworks related to securities issuance and listing rules, and details the sponsor's ongoing supervision activities, including review of governance, financials, internal controls, risk factors, and compliance. The document contains detailed financial data for 2024, risk disclosures, core competitiveness analysis, R&D progress, and management shareholding information. It is a comprehensive report on the sponsor's continuous supervision of the company post-issuance, which is a type of audit or regulatory oversight report rather than a full annual report or earnings release. It is not a transcript, presentation, or announcement. The document is substantive and detailed, not a brief announcement or certification. Therefore, it fits best under the category of Audit Report / Information (AR), which includes standalone audit reports and regulatory stress test results, excluding full annual reports. Confidence is high given the detailed supervisory content and financial data included. FY 2024
2025-05-21 Chinese
神州细胞第三届董事会第一次会议决议公告
Board/Management Information Classification · 100% confidence The document is a formal announcement of resolutions passed at the first meeting of the third board of directors of Beijing Shenzhou Cell Biotechnology Group Co., Ltd. It details the election and appointment of board members and senior management positions such as chairman, general manager, deputy general managers, financial director, board secretary, and securities affairs representative. It also includes approval of revisions to board committee working rules. The document is dated May 17, 2025, and references compliance with company law and internal regulations. There is no financial data, earnings information, or report publication mentioned. The content clearly relates to changes in the company's board and senior management. Therefore, the appropriate classification is Board/Management Information (MANG). The document length is 2091 characters, which is consistent with a detailed announcement rather than a full report.
2025-05-16 Chinese
北京市金杜律师事务所关于北京神州细胞生物技术集团股份公司2024年年度股东大会的法律意见书
Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document is a legal opinion letter from a law firm regarding the convening, attendance, voting procedures, and results of the 2024 Annual General Meeting (AGM) of Beijing Shenzhou Cell Biotechnology Group Co., Ltd. It details the legal compliance of the AGM process, the qualifications of attendees, and the voting outcomes on various resolutions including the annual report, board reports, financial reports, profit distribution, and board elections. The document does not contain the actual annual report or financial statements but rather provides legal assurance on the AGM procedures and results. This fits the category of Declaration of Voting Results & Voting Rights Announcements (DVA), as it officially reports the voting results of the AGM.
2025-05-16 Chinese
神州细胞关于公司董事会完成换届选举暨聘任高级管理人员的公告
Board/Management Information Classification · 95% confidence The document is an announcement regarding the completion of the company's board of directors re-election and the appointment of senior management personnel. It details the election results, committee formations, and appointments of key executives. The document references the company's articles of association, relevant laws, and previous announcements but does not contain financial statements or performance data. The content focuses on governance changes and management appointments rather than financial results or reports. Therefore, it fits the category of Board/Management Information (MANG). The document length is 2749 characters, which is relatively short and consistent with an announcement rather than a full report.
2025-05-16 Chinese

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.